EXCI excimer laser ablation uses 308nm light delivered through laser fiber catheters of different specifications to debulk and reopen stenotic/occluded coronary and peripheral vessels. It also supports transvenous removal of pacing/defibrillation leads. It plays an important role in intervention for complex coronary lesions, especially calcified lesions. Used with disposable ELCA laser fiber catheters, it treats in-stent restenosis by intimal debulking, lesions difficult to cross or dilate with balloons, and bypass-graft lesions. This advanced coronary precision-intervention equipment fills a domestic gap; globally, only one company, Philips in the USA, sells such equipment.
| Parameter | Value |
| Wavelength | 308 nm (nm) |
| Maximum single-pulse energy | >200 mJ (mJ) |
| Repetition rate | 1-80 Hertz (Hz) |
| Pulse width [Full Width at Half Maximum (FWHM)] | >120 ns (ns) |
| EXCI-Coronary Laser Atherectomy Catheter For ELCA-Max. Guidewire compatibility | 0.014 inch / 0.36 mm |
| EXCI-Coronary Laser Atherectomy Catheter For ELCA-Max. Tip Diameter | 0.059 inch / 1.50mm |
| EXCI-Coronary Laser Atherectomy Catheter For ELCA-Working length | 138 cm |
Applications: 1. For patients suitable for transvenous extraction, assists conventional lead tools in removing problematic pacemaker or defibrillator leads with silicone or polyurethane outer insulation. 2. Reopening severe lower-limb atherosclerotic stenoses and occlusions. 3. Intimal debulking for in-stent restenosis and treatment of lesions difficult to cross/dilate with balloons and bypass-graft lesions. 4. The ELCA Coronary Laser Ablation Catheter crosses, prepares and treats the most complex coronary lesions. This nonmechanical catheter travels over any 0.014-inch/0.36 mm guidewire, removing and modifying plaque to improve vessel conditions.
Fiber-optic catheter technology matched to the equipment.
Please provide your email to download the datasheet.
Hefei Excimer Laser Technology Co., Ltd. (For Short "EXCI") is founded by researchers from the Chinese Academy of Sciences. It is a world‑leading high‑tech enterprise specializing in independent R&D and industrialization of excimer lasers. The company focuses on complete‑machine R&D, large‑scale manufacturing and customized scenario‑oriented solution development for high‑end excimer lasers. Its products serve high‑end scientific research, precision industry and medical sectors, covering excimer laser annealing, lift‑off, repair, photolithography, pulsed laser deposition, superconducting tape fabrication, fiber Bragg grating inscription, and excimer laser medical devices. We provide standardized mass production, personalized customization and full‑life‑cycle maintenance services for multi‑power and multi‑category equipment.
Excimer laser technology represents a scarce core technology for high‑end equipment. Worldwide, only more than ten enterprises across six countries (China, Germany, the United States, Japan, Canada and Russia) possess independent mass‑production core capabilities. ExciLaser ranks among the world’s first‑tier players. Committed to independent and controllable core technologies, the company precisely fills domestic gaps in the high‑end excimer laser industry. It has overcome multiple key bottleneck technologies, realized domestic substitution of high‑end laser equipment, and effectively broken overseas technological monopolies.
Founded in March 2023, the company holds qualifications including National High‑Tech Enterprise, National Science‑ and Technology‑based Small‑ and Medium‑Sized Enterprise, and enterprise status in Hefei’s key industrial‑chain catalog. It has obtained ISO 9001 Quality Management System Certification. The company owns numerous invention patents, utility‑model patents and software copyrights, establishing a complete and independent intellectual‑property protection system to continuously underpin technological iteration, product upgrading and industrial implementation.